Evolution of mild cognitive impairment in Parkinson disease.

Neurology

Department of Brain and Cognition, University of Amsterdam, Amsterdam, the Netherlands.

Published: July 2013

Objective: We examined the development of Parkinson disease (PD)-mild cognitive impairment (MCI) in patients with newly diagnosed PD over 5 years using recently proposed consensus criteria, and we assessed the reliability of the criteria.

Methods: Patients with PD (n = 123) underwent extensive neuropsychological testing at baseline and after 3 (n = 93) and 5 years (n = 59). Two neuropsychologists independently applied the PD-MCI criteria to examine the interrater and intrarater reliability.

Results: At baseline, 35% of patients had PD-MCI. Three years later, 53% of the patients had PD-MCI. At 5-year follow-up, 20 patients who had PD-MCI at an earlier assessment had converted to PD dementia and 50% of the remaining patients without dementia had MCI. The interrater reliability (kappa) was 0.91. The intrarater reliabilities were 0.85 and 0.96.

Conclusion: Approximately one-third of patients with newly diagnosed PD fulfill the consensus criteria for PD-MCI; after 5 years, this proportion is approximately 50% of patients without dementia. The criteria have good interrater and intrarater reliability.

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e31829c5c86DOI Listing

Publication Analysis

Top Keywords

patients pd-mci
12
cognitive impairment
8
parkinson disease
8
patients
8
patients newly
8
newly diagnosed
8
consensus criteria
8
interrater intrarater
8
patients dementia
8
pd-mci
5

Similar Publications

A study on the exploration of mild cognitive impairment in Parkinson's disease based on decision-making cognitive computing.

Front Neurosci

January 2025

Department of Neurology, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China.

Mild cognitive impairment in Parkinson's disease (PD-MCI) as an independent risk factor for dementia in Parkinson's disease has prognostic value in predicting dementia in PD patients. It was found that the calculation of cognitive function decision-making could better evaluate the cognitive function of PD-MCI. Therefore, this study explored deficits in decision-making cognitive function in PD-MCI population, and mined novel digital biomarkers for recognizing early cognitive decline in PD-MCI through an independently designed maze decision-making digital assessment paradigm.

View Article and Find Full Text PDF

Rationale And Objectives: Cognitive disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD), significantly impact the quality of life in older adults. Mild cognitive impairment (MCI) is a critical stage for intervention and can predict the development of dementia. The causes of these two diseases are not fully understood, but there is an overlap in their neuropathology.

View Article and Find Full Text PDF

Introduction: This study investigated the cortical and subcortical gray matter volume (GMV) and cognitive impairment (CI) in patients with Parkinson's disease (PD).

Methods: In this study, T1-weighted magnetic resonance imaging of the cortex and subcortex was conducted on 92 individuals diagnosed with PD and 92 healthy controls (HCs). PD patients were divided into three groups: PD with normal cognition (PD-NC,  = 21), PD with mild CI (PD-MCI,  = 43), and PD with severe CI (PD-SCI,  = 28).

View Article and Find Full Text PDF

Association of plasma homocysteine with cognitive impairment in patients with Parkinson's disease.

Front Aging Neurosci

December 2024

Department of Neurology and National Research Center for Aging and Medicine and National Center for Neurological Disorders, State Key Laboratory of Medical Neurobiology, Huashan Hospital, Fudan University, Shanghai, China.

Background: Elevated plasma homocysteine (Hcy) has been reported as a risk factor for cognitive impairment in the general population. However, there are conflicting results regarding the relationship between Hcy and cognitive impairment across various cognitive domains in Parkinson's disease (PD).

Objective: This study aims to explore the association between plasma Hcy levels, cognitive impairment, and dysfunction in various cognitive domains among PD patients with and without mild cognitive impairment (MCI).

View Article and Find Full Text PDF

Background: A dual-syndrome hypothesis, which states the cognitive impairments in Parkinson's disease (PD) are attributable to frontostriatal dopaminergic dysregulation and cortical disturbance-each associated with attention/executive and memory/visuospatial dysfunction, respectively-has been widely accepted. This multisystem contribution also underlies highly heterogeneous progression rate to dementia.

Methods: Nondemented PD patients who underwent [I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ([I]FP-CIT) SPECT and neuropsychological examinations were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!